FDA delays decision on Sarepta’s Duchenne muscular dystrophy gene therapy by one month; Brain and spine implants allows a paralyzed man to walk naturally again; Eloxx Pharmaceuticals plans to move its lead candidate into a Phase 3 clinical trial.
Five things for pharma marketers to know: Wednesday, May 24, 2023
How Republican presidential candidate and former Roivant Sciences CEO Vivek Ramaswamy turned Martin Shkreli into the ‘Pharma Bro’; The FDA approves a new easy-to-use version of a medication to reverse overdoses caused by fentanyl; Ironwood bulks up on its digestive therapies with a $1.15 billion purchase of VectivBio.
Five things for pharma marketers to know: Tuesday, May 23, 2023
Pfizer’s oral weight loss drug may be as effective as and quicker than Ozempic injection by Novo Nordisk; Prelude Therapeutics, Cabaletta Bio raise around $161 million combined in public stock sales; Novartis bolstered its gene therapy pipeline by spending $87.5 million on an Avrobio therapy.
Five things for pharma marketers to know: Monday, May 22, 2023
Novartis drops some early-stage cancer drugs from its pipeline; FDA clears Thermo Fisher Scientific’s test to detect women with risk of severe preeclampsia; Moderna presents promising early data on its mRNA treatment for propionic acidemia.
Five things for pharma marketers to know: Friday, May 19, 2023
Eli Lilly’s treatment for rheumatoid arthritis meets main goal for efficacy; Eyepoint Pharmaceuticals sells Yutiq to Alimera Sciences for $82.5 million; A Midwest anti-abortion group uses cellphone location data to target online content to visitors of certain Planned Parenthood clinics.
Five things for pharma marketers to know: Thursday, May 18, 2023
Abcam founder Jonathan Milner seeks to oust the chairman of the biotech supplier; PTC Therapeutics’ phenylketonuria drug met its key goal in a Phase 3 study; Court rejects former Theranos CEO Elizabeth Holmes’ bid to remain free while she tries to overturn her conviction.
Five things for pharma marketers to know: Wednesday, May 17, 2023
Pfizer kicks off a jumbo bond sale to help fund its $43 billion acquisition of Seagen; Flagship Pioneering’s Metaphore Biotechnologies emerges from stealth mode with an initial $50 million; The White House summons naloxone manufacturers for a roundtable focused on the medication’s price.
Five things for pharma marketers to know: Tuesday, May 16, 2023
Supreme Court declines to hear Teva’s challenge to a $235 million award to GSK in patent dispute; President Biden nominates Monica Bertagnolli to run the National Institutes of Health; Athenex files for Chapter 11 bankruptcy and is seeking a buyer for its drug candidates.
Five things for pharma marketers to know: Monday, May 15, 2023
FDA advisors voiced concerns about Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy; Lawmakers ask regulators to investigate whether composition of panel overseeing animal testing at Elon Musk’s Neuralink contributed to botched experiments; HHS builds out Project NextGen to develop future COVID-19 vaccines.
Five things for pharma marketers to know: Friday, May 12, 2023
GSK plans to sell its $1 billion stake in Haleon; The World Health Organization says Mpox is no longer a global health emergency; The Food and Drug Administration rejects a biologics license application for a bladder cancer drug from Patrick Soon-Shiong’s ImmunityBio.